Search results
Results from the WOW.Com Content Network
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. [6] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.
Filgrastim is a recombinant form of the naturally occurring granulocyte colony-stimulating factor (G-CSF). [21] It works by stimulating the body to increase neutrophil production. [21] Filgrastim was approved for medical use in the United States in 1991. [21] It is on the World Health Organization's List of Essential Medicines.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Nine of them cost more than $2 million. A tenth, approved in November, is predicted to run about $3.8 million, just shy of the most expensive, also approved last year, which costs $4.25 million a ...
Sandoz's Zarxio is biosimilar to Amgen's Neupogen (filgrastim), which was originally licensed in 1991. This is the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), which was passed as part of the Affordable Healthcare Act.
Oncologists in the US have also used the BEACOPP regimen relatively less for cost reasons: Twice as many infusion per cycle relative to ABVD ; Requirement for G-CSF support, which was under patent protection in the US as late as 2013 (as Neupogen by Amgen), [ 4 ] while that patent protection expired in the EU in 2008; [ 5 ]
The term dosage form may also sometimes refer only to the pharmaceutical formulation of a drug product's constituent substances, without considering its final configuration as a consumable product (e.g., capsule, patch, etc.). Due to the somewhat ambiguous nature and overlap of these terms within the pharmaceutical industry, caution is ...
In 2023, more than five million Americans 12 and older reported a "prescription use disorder" within the past year, according to the Centers for Disease Control and Prevention (CDC).